The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

Welcome to the fourth quarter 2024 Illumina earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference ...

Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling ...

Illumina is down 15.2% since the beginning of the year, and at $111.06 per share, it is trading 28.4% below its 52-week high of $155.15 from November 2024. Investors who bought $1,000 worth of ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

On Monday, for the second time in as many business days, Illumina ( ILMN -4.11%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% ...

Barclays downgraded Illumina (ILMN) to Underweight from Equal Weight.Maximize Your Portfolio with Data Driven Insights:Leverage the power of ...

Fintel reports that on February 10, 2025, Barclays downgraded their outlook for Illumina (NasdaqGS:ILMN) from Equal-Weight to ...

That morning, Barclays changed its recommendation on Illumina stock to underweight (read: sell) from the previous equal weight (hold). It also pulled the lever on a significant price target ...

Non-GAAP tax provision excludes the effects of the pro forma adjustments detailed above, which have been excluded to assist investors in analyzing and assessing past and future operating ...

Shares of Illumina (NASDAQ: ILMN) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. ET. At that time ...